Pravastatin has no direct effect on transmembrane cationic transport systems in human erythrocytes and platelets.
In vitro incubation of human erythrocytes and platelets with the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin in the concentration range 1 nM to 10 microM did not affect the activity of the Na(+)-K(+)-pump, Na(+)-K(+)-cotransport or Na(+)-Li(+)-countertransport, or the ground membrane leak for Na+ and K+. The data indicate that pravastatin has no direct effect on transmembrane cationic transport systems in red blood cells or platelets.
Lijnen
P
P
Hypertension Unit, Campus Gasthuisberg, Leuven, Belgium.
Petrov
V
V
Amery
A
A
D017920:Antiporters / Q000187:drug effects* / Q000378:metabolism*; D001693:Biological Transport, Active / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism*; D002352:Carrier Proteins / Q000187:drug effects* / Q000378:metabolism*; D002412:Cations / Q000378:metabolism / Q000493:pharmacokinetics; D002462:Cell Membrane / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D004910:Erythrocyte Membrane / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism*; D006801:Humans; D010042:Ouabain / Q000494:pharmacology; D011188:Potassium / Q000378:metabolism* / Q000493:pharmacokinetics; D017035:Pravastatin / Q000494:pharmacology*; D012413:Rubidium / Q000493:pharmacokinetics; D012414:Rubidium Radioisotopes; D012964:Sodium / Q000378:metabolism* / Q000493:pharmacokinetics; D028021:Sodium-Potassium-Chloride Symporters; D000254:Sodium-Potassium-Exchanging ATPase / Q000187:drug effects* / Q000378:metabolism*
D017920:Antiporters; D002352:Carrier Proteins; D002412:Cations; D012414:Rubidium Radioisotopes; D028021:Sodium-Potassium-Chloride Symporters; C045885:sodium-lithium countertransporter; D010042:Ouabain; D012964:Sodium; D000254:Sodium-Potassium-Exchanging ATPase; D017035:Pravastatin; D012413:Rubidium; D011188:Potassium